Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a strategic partnership with US cancer therapy developer Parthenon Therapeutics Inc. to develop antibodies targeting solid tumors. This collaboration aims to leverage the power of AI to advance oncology treatments.
Access to XtalPi’s XupremAb Platform and “Experiment+AI” Solutions
Under the terms of the partnership, Parthenon will be granted access to XtalPi’s XupremAb antibody discovery platform, which encompasses a range of “experiment+AI” technical solutions. The platform is designed to integrate experimental data with AI-driven analytics to enhance the discovery process.
In-Depth Analysis and Database Generation
The two companies will employ various discovery methods on the XupremAb platform to conduct comprehensive analysis of the immune library. This process will involve generating a large, integrated database, which will then be mined using XtalPi’s proprietary algorithms to identify candidate antibody molecules. The goal is to develop novel antibodies with potential therapeutic applications in oncology.
Financial Details and Future Implications
No financial details of the partnership were disclosed, but the collaboration signals a significant step forward in the integration of AI technology into the development of targeted cancer therapies. The partnership between XtalPi and Parthenon Therapeutics highlights the growing trend of leveraging AI to enhance drug discovery and development processes.-Fineline Info & Tech
